Mr. James Barlow became the CEO of ImmunoGenesis in April 2020. Since joining ImmunoGenesis, he has raised of over $35M in capital, including a $15.5M CPRIT Product Development grant. The company is poised to begin two clinical trials, one of which is the Phase 1a/1b trial for IMGS-001, the drug being supported by the CPRIT grant. IMGS-001, a PD-L1/PD-L2 dual-specific with engineered cytotoxic effector function, is a revolutionary PD-1 pathway targeting molecule. Before joining ImmunoGenesis, Mr. Barlow was VP of Ops and BD for Geneos Therapeutics. Mr. Barlow played an integral role in the formation of Geneos, a personalized neoantigen-targeting cancer vaccine company spun off from Inovio Pharmaceuticals. One of two initial employees, he led the tumor prioritization efforts, resulting in the design and initiation of the company’s first clinical trial less than nine months after obtaining Series A financing. Before joining Geneos, Mr. Barlow drove the development of Inovio’s Immunooncology product strategy. In this effort, he led a crossfunctional team across Commercial, Clinical, Product Development, R&D, and Business Development. His leadership resulted in the company embarking on major clinical programs across four tumor types.
Prior to Inovio, Mr. Barlow was at BristolMyers Squibb (BMS), where he was the Payer Marketing Lead for YERVOY®, the pioneering cancer immunotherapy whose approval set off the current wave of immunotherapy development in oncology. While at BMS, Mr. Barlow also worked on the launch of the groundbreaking immunotherapy, OPDIVO®. Before his tenure at BMS, he spent eight years at Merck working in commercial leadership roles in the oncology franchise. Mr. Barlow received an MBA (strategy and marketing) with honors from the Tepper School of Business at Carnegie Mellon University. He was awarded the Dean’s Scholarship from Tepper. Mr. Barlow received a B.A. in Math and Economics from Colgate University, where he was awarded the Alumni Memorial Scholarship and graduated summa cum laude.Sessions: